ACT Genomics

🧬Unveiling Our New Logo: A Symbol of Hope and Innovation🧬 Introducing our brand new logo symbolizes our unwavering commitment to progress and excellence in the healthcare industry. This refreshed identity embodies our core values and aspirations for the future. Our new logo boats simplified hexagons, representing the molecular structure of DNA bases. The merging of two hexagons symbolizes the DNA double helix and the concept of "infinite hope." The vibrant blue hue conveys professionalism, innovation, and a deep sense of care. #ACTGenomics  #genomics #personalizedmedicine #precisionmedicine #futureofhealthcare

We’re excited to announce a new partnership between ACT Genomics and mProbe Inc. to advance precision medicine in Asia! This collaboration will focus on expanding access to mProbe's innovative proteomics technology for oncology diagnostics across key markets. Together, we aim to enhance cancer diagnosis and treatment outcomes. #PrecisionMedicine #Oncology #AsianMarkets #HealthcareInnovation The full article: https://smpl.is/9rpad

Let's take a deep dive into hereditary cancer syndromes. They are genetic disorders that significantly increase an individual's risk of developing certain types of cancer. Unlike sporadic cancers, which occur due to random genetic mutations over a person's lifetime, hereditary cancers result from inherited gene mutations passed down through parents. Full article: https://smpl.is/9rh5z

We had the privilege of co-hosting an enlightening event with the Precision Oncology Society, bringing together experts in oncology and precision medicine in Hong Kong. The evening featured presentations such as Professor Qin's talk on Protein Science and Technology. As a leader in proteomics, he shared his groundbreaking research on protein science. Dr. Joseph Siu-Kie AU, President of the Hong Kong Precision, highlighted that the current process for new drug registration is insufficient to meet the needs of patients with refractory or recurrent cancers. He suggested that establishing a Multidisciplinary Team (MDT) and a basket clinical trial to direct these patients to various clinical trials in the Greater Bay Area (GBA) could be an effective solution. Additionally, the discussion on refractory solid tumors provided valuable insights into addressing some of the most challenging cases in cancer treatment, along with the latest updates from ACT Genomics’ technology. We are thankful to everyone who attended and contributed to this impactful evening.

Proud to share that ACT Genomics (Hong Kong) Limited and Cancerinformation have signed a Memorandum of Understanding (MOU) to enhance cancer patients' understanding of cancer and the importance of precision medicine. This collaboration aims to empower patients through education and increase accessibility to genetic testing. By offering a special promotion on genetic screenings at public hospitals for Cancerinformation members, we strive to lower barriers and make precision medicine more accessible and widespread. Together, we are committed to making precision medicine more accessible! Read more: https://smpl.is/9lodl

Delighted to share ACT Genomics participated in the 2024 annual meeting of Thai Gynecologic Cancer Society (TGCS). Such an honor to meet and discuss #gynecologic related subjects with physicians, it's always encouraging to make insightful discussion with people who makes precision medicine accessible!

We are proud to share the collaboration with TaiwanPlus to showcase our working culture and environment, presented by our director of research and development, Dr. Prerana Bhan. At ACT Genomics, we celebrate the multicultural working environment, and we look forward to more global talents in Taiwan.

We are honored to be part of the 25th Anniversary of the #LampangCancerHospital Conference. The insightful session "Expanding in Clinical Molecular NGS Testing & HRD" by Dr. Yotsawaj Runglodvatana brought in new ideas. Join us in exploring the possibilities of NGS in Thailand. Watch the session (Starting from 40 mins): ttps://https://lnkd.in/g9xzNS8x

Several promising biomarker-related treatment data for #GI cancer were released at the American Society of Clinical Oncology (#ASCO) 2024 annual meeting. Join us in finding out more: https://smpl.is/9j7cy ⭐ KRAS G12C-mutated mCRC (PhaseIII CodeBreaK 300 Trial) ⭐ HER2-positive mCRC (PhaseII MOUNTAINEER Trial) ⭐Acquired gene alterationpatterns in RASwt mCRC after 1L treatments (Phase III PARADIGM trial) ⭐HER2-positive BTC (Phase2b HERIZON-BTC-01 study) ⭐Sitravatinib andtislelizumab combination in 2L setting of advanced BTC (Phase II BTC-BGB trial)

We are honored to have Professor Mok for an enlightening sharing of valuable insights and learnings from #ASCO2024 alongside our CEO, Walt Ling, and esteemed local physicians in Hong Kong. This special event, held in Hong Kong, brought together leading physicians and industry experts to discuss the latest advancements and innovations in oncology. It was a great opportunity to connect, learn, and discuss how these developments can be integrated into practice to enhance patient care.